หน้าแรก
ค้นหา
Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma
Dr. Jeffrey Weber on Optimal Therapy Sequences in Advanced Melanoma
Dr. Jeffrey Weber on Ipilimumab for Melanoma
Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma
Dr. Jeffrey Weber Explores Nivolumab in Advanced Melanoma
Dr. Jeffrey Weber on Potential Breakthrough "Cures" in Melanoma
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker
Sequencing of Checkpoint Agents in Melanoma
Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab
Oncologist Omid Hamid on Calming Fears of Patients with Metastatic Melanoma
New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma
Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma
Dr. Weber Discusses Toxicity of Immunotherapies in Melanoma
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma
Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising
Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma
Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma Patients
